Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer

Abstract Multimodal therapies were combined to eradicate the primary site, metastatic, and micrometastatic disease in men with newly diagnosed, synchronous, oligometastatic prostate cancer. The investigation included companion, phase II studies: total eradication therapy-1 (TET-1) for those treatment-naïve and total eradication therapy-2 (TET-2) for those post-prostatectomy. The treatment-naive protocol included androgen deprivation and docetaxel (with concurrent abiraterone added in a protocol amendment), followed by a prostatectomy, adjuvant radiation (if positive margins, T3/4, or detectable PSA), and metastasis-directed therapy. The post-prostatectomy protocol assigned the same therapies (omitting the prostatectomy). The primary endpoint was an undetectable PSA with recovered testosterone. The safety boundaries were ≤ 50% for grade 3/4 neutropenic and ≤ 20% for grade 3/4 surgical- and radiation-related toxicities. Enrollment was planned for 60 patients per protocol, to detect a PSA progression-free survival ≥ 32%, as compared to 15% in a historic control. Enrollment closed early. An interim analysis was conducted once > 50% of patients were evaluable for the primary endpoint. The primary endpoint duration was assessed by median progression-free survival. 52 patients were enrolled (n = 26 per protocol). Medium follow-up was 30.3 months. 80% (24/30) of evaluable patients achieved the primary endpoint; the duration was not reached. Of those not evaluable, 77% (17/22) had not reached the endpoint and 23% (5/22) had exited. There were 8% (4/52) grade 3/4 neutropenic and 2% (1/48) grade 3/4 surgical or radiation-induced toxicities. Interim findings suggest the trials’ endpoints were met, advancing the concept of total eradication therapy in men with oligometastatic prostate cancer..

Medienart:

E-Artikel

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Zur Gesamtaufnahme - volume:39

Enthalten in:

Medical oncology - 39(2022), 6 vom: 28. Apr.

Sprache:

Englisch

Beteiligte Personen:

Reyes, Diane K. [VerfasserIn]
Trock, Bruce J. [VerfasserIn]
Tran, Phuoc T. [VerfasserIn]
Pavlovich, Christian P. [VerfasserIn]
Deville, Curtiland [VerfasserIn]
Allaf, Mohamad E. [VerfasserIn]
Greco, Stephen C. [VerfasserIn]
Song, Daniel Y. [VerfasserIn]
Bivalacqua, Trinity J. [VerfasserIn]
Han, Misop [VerfasserIn]
Partin, Alan W. [VerfasserIn]
Sartor, A. Oliver [VerfasserIn]
Rowe, Steven P. [VerfasserIn]
Pienta, Kenneth J. [VerfasserIn]

Links:

Volltext [lizenzpflichtig]

BKL:

44.81$jOnkologie

Themen:

Multi-modal therapy
Oligometastatic prostate cancer
Total eradication therapy

Anmerkungen:

© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

doi:

10.1007/s12032-022-01662-7

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

OLC213029491X

Zugang & Verfügbarkeit




Zugehörige Publikationen/Bände

    Haven't found what you're looking for?